I'll research BIIB before writing the preview. Let me start by gathering recent earnings materials, news, and stock data.Let me read the most recent earnings call and release, plus get recent news and stock price data.I have rich material. Let me pull the exact FY2026 guidance from the Q1 release and check on the Apellis deal close and analyst positioning.The Apellis deal closed May 14. Let me read the acquisition 8-K and the July 1 guidance 8-K to capture what's changed heading into Q2.Let me check on the key May catalyst — the LEQEMBI subcutaneous initiation PDUFA (May 24) outcome — and recent analyst sentiment.I now have what I need. Here's the earnings preview.

Biogen (BIIB) — 2026 Q2 Earnings Preview

Report date: Wednesday, July 29, 2026 (before market open) | Event: 2026 Q2 Earnings Call

The one-line setup

This is a transition quarter dominated by non-operating noise. It will be the first report that consolidates Apellis (SYFOVRE + EMPAVELI), the first to fold in a large, pre-flagged in-process R&D (IPR&D) charge, and the quarter where management delivers its first full-year 2026 guidance inclusive of Apellis. Underneath the accounting distortion, the story investors actually care about — can the "growth portfolio" offset MS erosion fast enough, and does the late-stage pipeline still justify the re-rating — is largely unchanged. Watch the guidance and the qualitative franchise commentary far more than the headline EPS print.

1. Why the EPS headline will look messy (and how to read it)

Two pre-announced items make the Q2 non-GAAP EPS number nearly uncomparable to consensus history:

A large IPR&D charge. In a July 1 8-K, Biogen guided that Q2 GAAP/non-GAAP results will include ~$164M of acquired IPR&D/upfront/milestone expense (~$0.95 EPS hit). It also flagged an even larger Q3 charge of ~$290–320M (~$1.75–$1.95 EPS) tied to milestones/deals not yet closed. Biogen (unusually) includes IPR&D in its non-GAAP EPS, so these charges depress the "adjusted" number that screens use.
Apellis dilution. The deal closed May 14, 2026, so Q2 carries ~six weeks of SYFOVRE/EMPAVELI revenue but also acquisition financing costs. Management guided to roughly $120–130M of incremental non-GAAP other expense in 2026 (financing + foregone interest income).

Implication: Sell-side consensus is scattered — some stale estimates still sit near $3+, while charge-adjusted views (e.g., Zacks) cluster near ~$0.79 EPS on ~$2.47B revenue. Because of the IPR&D and Apellis noise, I'd de-emphasize the EPS beat/miss and focus on (a) revenue vs. the ~$2.4–2.5B range, (b) growth-product momentum, and (c) the new guide.

2. The single most important deliverable: Apellis-inclusive 2026 guidance

Management explicitly deferred consolidated guidance in Q1 and promised to provide it with Q2. The reference points going in:

Prior standalone 2026 guide (ex-Apellis): non-GAAP EPS $14.25–$15.25 (already cut ~$1.00 from the original $15.25–$16.25 to absorb IPR&D, including ~$0.55 for the TJ Biopharma/felzartamab China rights and ~$0.25 for the salanersen STELLAR-1 milestone); total revenue down mid-single digits vs. 2025; gross margin and combined R&D+SG&A roughly flat; non-GAAP tax rate ~17–18%.
What changes with Apellis: two commercial products added to the top line, offset by financing costs and additional IPR&D. Management has framed Apellis as accretive in 2027 (not 2026) and as materially lifting the EPS growth trajectory through 2030.

Key questions: How much SYFOVRE/EMPAVELI revenue is baked into 2H26? Where does net interest expense land? And does the underlying (ex-charge) EPS power still support the "return to growth" narrative? Any confirmation that the underlying business is tracking to or above the standalone range would be reassuring.

3. Commercial franchise — the real engine

In Q1, growth products generated $851M, +12% y/y, and for the first time out-earned the remaining (non-VUMERITY) MS portfolio. Watch these lines:

Product	Q1'26	Y/Y	What to watch in Q2
LEQEMBI (BIIB 50% share; end-market $168M)	$168M end-mkt / $86M US	+74%	Sequential US/Japan/China growth; *IQLIK subcutaneous initiation* was FDA-approved July 13** (launch late August) — a real convenience catalyst vs. Kisunla; watch Kisunla-to-LEQEMBI maintenance switching
SKYCLARYS	$151M	+22%	Lumpy on US inventory/pricing; ex-US now exceeds US and is the growth driver (35 countries)
ZURZUVAE	$55M	+100%	Demand trajectory; DTC spend
VUMERITY	$179M	+29%	Note Q1 was inventory-aided — watch for give-back
SPINRAZA	$374M	−12%	High-dose regimen now launched in US/EU/Japan (~20% early conversion) — key to stabilizing/defending the franchise; shipments are inherently lumpy ex-US
QALSODY	$33M	+110%	Small but fast-growing
MS base (TECFIDERA, AVONEX, etc.)	—	declining	Structural erosion continues; TYSABRI Q1 was flattered by ~$59M of one-time inventory/discount items

Newly added (Apellis): SYFOVRE (geographic atrophy) and EMPAVELI (PNH/C3G/IC-MPGN). Management is downplaying a near-term SYFOVRE inflection but sees a large untreated GA population (~1.5M patients, only ~20% treated) and leans on SYFOVRE's 5-year lesion-growth data as a "data moat" vs. C5 competitors (IZERVAY, Regeneron, Annexon). First read on how the integrated commercial engine is being deployed will matter.

4. Balance sheet / capital allocation

Apellis was ~$5.3B, at $41/share + one CVR per share worth up to $4.00, tied to SYFOVRE annual net-sales milestones ($1.5B and $2.0B thresholds across 2027–2031; max CVR payout ~$582M).
Funded with ~$3.6B balance-sheet cash + $2.0B in term loans (a $1B 364-day tranche and a $1B two-year tranche); Biogen targets deleveraging by end-2027 and has a 3.75x leverage covenant.
Q1 exit: ~$4.7B cash, ~$1.5B net debt, strong FCF ($594M in Q1). Post-close net debt will be materially higher — watch updated net-debt and the deleveraging path.

5. Pipeline — the overhang and the catalysts

The overhang: diranersen (BIIB080, anti-tau ASO). The Phase 2 CELIA study missed its prespecified dose-response primary endpoint in May, and detailed data at AAIC (London, mid-July) left investors unconvinced — the lowest dose showed ~26% less cognitive decline vs. placebo, but benefit was inverse to dose. Shares fell ~6–8% on the readouts. Biogen is nonetheless advancing to Phase 3 (years from data). Expect pointed Q&A on the go-forward rationale, dose/regimen selection, and spend discipline; this remains a sentiment risk but is not core to near-term numbers.

The catalysts that support the growth thesis (a multi-year registrational cycle Biogen has emphasized): - Litifilimab — two Phase 3 SLE readouts expected this year; CLE readout early 2027 (breakthrough designation in CLE; two positive Phase 2 CLE datasets). Potential anchor of a lupus franchise (alongside UCB-partnered dapirolizumab). - Felzartamab (now worldwide rights incl. China) — first Phase 3 readout in AMR expected 2027; positioned as the core of a new nephrology franchise leveraging the Apellis/EMPAVELI commercial footprint. - Salanersen — pivotal STELLAR-1 dosed its first patient; durable Phase 1b data support once-yearly SMA dosing. - Zorevunersen (Dravet) Phase 3; LEQEMBI AHEAD 3-45 presymptomatic readout in 2028.

6. Stock setup & positioning

BIIB has rerated ~16% YTD (≈$178 → ≈$206 into the print), with a late-June high near $216 before the diranersen data pulled it back to the low-$190s, then a recovery to ~$205.
The move reflects the "growth-on-a-growing-base" narrative management sold around Apellis, partly offset by the diranersen disappointment.
What likely moves the stock: (1) the Apellis-inclusive guide vs. the ~$14.25–$15.25 standalone anchor; (2) whether growth products (esp. LEQEMBI trajectory + SKYCLARYS + SPINRAZA HD conversion) are offsetting MS erosion faster than modeled; (3) any early SYFOVRE/EMPAVELI datapoints and integration color; (4) tone/spend discipline on diranersen Phase 3.
Risk skew: Headline EPS will look ugly on the IPR&D charge — the risk is an algorithmic "miss" headline that obscures in-line-to-better operations. Conversely, a soft underlying revenue print or a conservative Apellis-inclusive guide could pressure a stock that has already run.

Bottom line

Look through the charge-distorted EPS. The three things that matter: (1) the first Apellis-inclusive 2026 guide and whether it preserves the return-to-growth story, (2) growth-portfolio momentum (LEQEMBI + IQLIK subcu launch, SKYCLARYS ex-US, SPINRAZA high-dose conversion) against continued MS decline, and (3) management's framing of the pipeline post-diranersen, particularly the near-term litifilimab SLE and 2027 felzartamab readouts that underpin the valuation.

Preview based on Biogen's Q1 2026 results and call, the April 29 and July 1 2026 8-Ks, the May 14 Apellis-closing 8-K/CVR terms, the July 13 LEQEMBI IQLIK approval, July AAIC diranersen coverage, and market data through July 28, 2026. Not investment advice; figures are non-GAAP unless noted and consensus estimates vary widely due to the IPR&D/Apellis distortions.